UroGen Pharma (NASDAQ:URGN) Now Covered by Scotiabank

Scotiabank started coverage on shares of UroGen Pharma (NASDAQ:URGN - Free Report) in a research note released on Wednesday morning, Marketbeat reports. The firm issued a sector outperform rating and a $23.00 price objective on the stock.

Other analysts have also issued research reports about the stock. HC Wainwright decreased their target price on shares of UroGen Pharma from $64.00 to $55.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. LADENBURG THALM/SH SH began coverage on UroGen Pharma in a research note on Wednesday, February 19th. They issued a "buy" rating and a $31.00 target price for the company. Finally, D. Boral Capital reissued a "buy" rating and issued a $25.00 price target on shares of UroGen Pharma in a research note on Monday, March 10th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $32.86.

UroGen Pharma Price Performance

URGN stock traded down $0.06 on Wednesday, reaching $9.61. The company had a trading volume of 169,019 shares, compared to its average volume of 510,439. The company's fifty day moving average is $10.49 and its 200 day moving average is $11.17. The company has a market cap of $442.96 million, a P/E ratio of -3.05 and a beta of 0.80. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. UroGen Pharma has a 1 year low of $8.94 and a 1 year high of $20.70.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings data on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The company had revenue of $24.57 million during the quarter, compared to analysts' expectations of $25.25 million. On average, research analysts forecast that UroGen Pharma will post -3.12 earnings per share for the current year.

Insider Buying and Selling at UroGen Pharma

In other UroGen Pharma news, General Counsel Jason Drew Smith sold 7,379 shares of the business's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the transaction, the general counsel now owns 26,468 shares in the company, valued at $294,853.52. The trade was a 21.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the sale, the insider now owns 145,666 shares of the company's stock, valued at approximately $1,622,719.24. This trade represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On UroGen Pharma

A number of institutional investors have recently added to or reduced their stakes in the company. Toronto Dominion Bank purchased a new position in UroGen Pharma in the fourth quarter valued at about $18,628,000. Acorn Capital Advisors LLC acquired a new stake in shares of UroGen Pharma during the fourth quarter worth approximately $16,149,000. Nantahala Capital Management LLC acquired a new stake in UroGen Pharma in the fourth quarter valued at $14,608,000. Vestal Point Capital LP boosted its stake in UroGen Pharma by 307.5% during the 4th quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company's stock valued at $17,360,000 after acquiring an additional 1,230,000 shares during the last quarter. Finally, Rosalind Advisors Inc. bought a new stake in shares of UroGen Pharma in the 4th quarter worth about $9,266,000. Institutional investors and hedge funds own 91.29% of the company's stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.